Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Atlantic Edge Private Wealth Management LLC

Atlantic Edge Private Wealth Management LLC grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.2% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 1,703 shares of the biopharmaceutical company’s stock after purchasing an additional 20 shares during the period. Atlantic Edge Private Wealth Management LLC’s holdings in Regeneron Pharmaceuticals were worth $1,213,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Rakuten Securities Inc. boosted its stake in Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 19 shares during the last quarter. FSA Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth about $26,000. Fairfield Financial Advisors LTD bought a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at about $37,000. Truvestments Capital LLC bought a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at about $39,000. Finally, Valley Wealth Managers Inc. bought a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at about $49,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Down 2.8 %

Shares of Regeneron Pharmaceuticals stock opened at $690.36 on Tuesday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 4.46. The company has a market capitalization of $75.86 billion, a price-to-earnings ratio of 18.03, a P/E/G ratio of 2.38 and a beta of 0.08. The business has a fifty day simple moving average of $715.81 and a two-hundred day simple moving average of $909.02.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter last year, the business earned $11.86 earnings per share. Regeneron Pharmaceuticals’s revenue was up 10.3% on a year-over-year basis. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 36.67 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.51%. The ex-dividend date of this dividend is Thursday, February 20th.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Sanford C. Bernstein reduced their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. BMO Capital Markets reduced their price target on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a research report on Tuesday, February 4th. Leerink Partners raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. Wolfe Research assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price objective on the stock. Finally, Truist Financial reduced their price objective on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.